Companies / Health Care
ZTS
Zoetis
Pharmaceuticals
PharmaceuticalsAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health76
Growth38
Profitability100
Cash generation83
Balance sheet63
Dilution control96
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)-1.3%Revenue growth (FY)2.3%Revenue CAGR (3y)5.4%Gross margin71.8%Operating margin—Net margin28.2%Free cash flow margin24.1%R&D / revenue7.4%Stock comp / revenue0.9%Net debt / operating cash flow2.32xCurrent ratio3.03Diluted share count change-2.4%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |
| Gross profit | $5.5B | $5.6B | $6.0B | $6.5B | $6.8B |
| Net income | $2.0B | $2.1B | $2.3B | $2.5B | $2.7B |
| Operating cash flow | $2.2B | $1.9B | $2.4B | $3.0B | $2.9B |
| Capital expenditure | $477M | $586M | $732M | $655M | $621M |
| Free cash flow | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B |
| R&D | $508M | $539M | $614M | $686M | $698M |
| Stock-based comp | $58M | $62M | $60M | $74M | $83M |
| Buybacks | $743M | $1.6B | $1.1B | $1.9B | $3.2B |
| Cash | $3.5B | $3.6B | $2.0B | $2.0B | $2.3B |
| Total debt | $6.6B | $7.9B | $6.6B | $6.6B | $9.0B |
| Equity | $4.5B | $4.4B | $5.0B | $4.8B | $3.3B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.